ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Jan C. Buckner, MD, on Whole-Brain Radiation and Radiosurgery in Patients With Brain Metastases

Jan C. Buckner, MD, of the Mayo Clinic discusses adjuvant whole-brain radiotherapy and the need for initial treatment with radiosurgery and close monitoring to preserve cognitive function in patients with brain metastases (Abstract LBA4).

Lung Cancer

Luis G. Paz-Ares, MD, PhD

Luis G. Paz-Ares, MD, PhD, Summarizes Results of the CheckMate 057 Trial on Nonsquamous Cell NSCLC

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario Doce De Octubre, discusses the superior overall survival in patients taking nivolumab vs docetaxel in advanced nonsquamous NSCLC (Abstract LBA109).

Leukemia

Lymphoma

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

James O. Armitage, MD, of the University of Nebraska Medical Center, and Asher Alban Akmal Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discuss an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).

Global Cancer Care

Health-Care Policy

Lawrence N. Shulman, MD and Clifford A. Hudis, MD

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.

Hematologic Malignancies

Ruben A. Mesa, MD

Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Jun

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Jan C. Buckner, MD, on Whole-Brain Radiation and Radiosurgery in Patients With Brain Metastases

Luis G. Paz-Ares, MD, PhD, Summarizes Results of the CheckMate 057 Trial on Nonsquamous Cell NSCLC

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

Outcomes With HSCT in Pediatric High-Risk AML

Investigational Menin Inhibitor Under Study in NPM1-Mutant AML

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN

Ciltacabtagene Autoleucel Delivers Lasting Remissions in Relapsed or Refractory Multiple Myeloma